News

News Aug 16, 2024

This Week in Drug Pricing: CMS announces reduced Medicare negotiation prices, and the Inflation Reduction Act turns two,

On Thursday the Centers For Medicare & Medicaid Services (CMS) published the first-ever, lower negotiated prices for all 10 high-cost drugs selected for the inaugural round of Medicare negotiation as…

Read Article News Aug 9, 2024

This Week in Drug Pricing: The Inflation Reduction Act Turns Two, Court Watch: US v. Pharma, and Big Pharma Patent Gaming

The Inflation Reduction Act’s second anniversary marks a major milestone in the drug pricing landscape.

Read Article News Aug 3, 2024

This Week in Drug Pricing: Court Watch: US V. Pharma, End Of Medicare Negotiation For First 10 Drugs, and ICYMI

A federal judge in New Jersey ruled against Novo Nordisk on Wednesday, rejecting all of the company’s arguments in its lawsuit aimed at stopping the historic Medicare negotiation program.

Read Article News Jul 26, 2024

This Week in Drug Pricing: PBM Showdown In The House, Drugs Corporations Rake In Profits, Court Watch: US V. Pharma, and ICYMI

The House Committee on Oversight and Accountability continued its 32-month investigation into pharmacy benefit managers (PBMs) with a hearing scrutinizing the middlemen’s shady practices that drive…

Read Article News Jul 19, 2024

This Week in Drug Pricing: Drugmaker’s Mid-Year Money Grab, Debunking Pharma’s Dual Narrative, and ICYMI

Between June 30th and July 5th, drug companies hiked the prices of 195 prescription drugs, with 50 percent of those increases exceeding the rate of inflation.

Read Article News Jul 12, 2024

This Week in Drug Pricing: Bipartisan Patent Thicket Legislation Unanimously Clears The Senate, FTC’s Scathing Report On PBMs, Fact V. Pharma Fear Mongering, and ICYMI

Marking an important victory for patients, yesterday the Senate unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S. 150), a bipartisan bill aimed at curbing the drug…

Read Article News Jul 5, 2024

This Week in Drug Pricing: Patients Score Fifth Legal Victory, Zeroing In On Patent Abuses, Expansion of Medicare Negotiation, Eli Lilly’s Pricey Alzheimer’s Treatment, and ICYMI

A federal judge in Connecticut dealt a fifth consecutive blow to the pharmaceutical industry’s legal campaign to halt the Medicare negotiation program.

Read Article News Jun 28, 2024

This Week in Drug Pricing: Inflation Penalties Drive Patient Savings, TIME Magazine Highlights P4AD Patient Advocates, Digital Day of Action: Defending Medicare Negotiation, and ICYMI.

Great news for Medicare as the Department of Health & Human Services (HHS) announced that the Inflation Rebate Program in the Inflation Reduction Act is already yielding significant benefits for some patients.

Read Article News Jun 21, 2024

This Week in Drug Pricing: Boehringer opposes Medicare negotiation, P4AD Founder David Mitchell debunks Pharma’s claims about the IRA, CBO estimates $5B savings from bipartisan bills against pharma’s anti-competitive tactics.

Another judge has cast doubt on pharma’s arguments challenging Medicare negotiation.

Read Article News Jun 14, 2024

This Week in Drug Pricing: P4AD Calls Out Big Pharma & PBMs At AHIP 2024, Patent Expiration Opens The Door For Lower Prices, and Legislator Pressure Pharma To Curb Patent Abuse

On Tuesday, at this year’s AHIP conference, P4AD Executive Director Merith Basey participated in a keynote panel titled, “Making Prescription Drugs Affordable and Accessible for Everyone,” where she…

Read Article